biocryst

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) were trading lower by more than 65 percent early Monday morning after the company reported disappointing results from a clinical trial. BioCryst designs, optimizes and develops novel small molecule drugs that block key enzymes involved in...

Baker Brothers Advisors, a hedge fund run by Julian and Felix Baker, disclosed after Monday's market close it acquired 106,800 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) for $7.28 per share. BioCryst Pharmaceuticals is a biotechnology company that develops small molecule drugs...

Rodman & Renshaw reiterates its Market Outperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX). At the same time, Rodman & Renshaw left its price target unchanged at $7. In a research report published today, Rodman & Renshaw states, "We are reiterating our Market Outperform /...

Rodman & Renshaw has upgraded BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) from Market Perform to Market Outperform with a $7 price target. BioCryst Pharmaceuticals closed yesterday at $4.82. Is AAPL a Buy, Sell or Hold? Click Here.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that it will host and webcast its Investor Day in New York City on Thursday, September 16, 2010 from 9 a.m. to 12 p.m. Eastern Time. BioCryst’s management team will provide a comprehensive overview of BioCryst’s strategy and clinical...